Vertex Pharmaceuticals (VRTX) Expands Board to Eleven Members wi

Vertex Pharmaceuticals Incorporated (VRTX) announced that Daniel Brennan has been appointed as a new member of its board of directors, effective October 20, 20

Veteran finance executive brings decades of healthcare and medical technology experience to Vertex's board and audit committee

Vertex Pharmaceuticals Incorporated VRTX announced that Daniel Brennan has been appointed as a new member of its board of directors, effective October 20, 2026. In connection with his appointment, the size of the board was increased from ten to eleven members. Mr. Brennan has also joined the company's Audit and Finance Committee.

Mr. Brennan brings extensive financial leadership experience to the role. He served as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a medical device and healthcare technology company, from January 2014 until his retirement in June 2025. Prior to that, he was Senior Vice President and Corporate Controller from 2010 through 2013, and he held various roles of increasing responsibility within the finance function from 1996 through 2009.

In addition to his executive career, Mr. Brennan has served on the board of directors of Waters Corporation, a publicly listed company focused on the development of analytical instruments and software, since November 2022. He has also served on the board of directors of Madrigal Pharmaceuticals, a publicly traded biopharmaceutical company, since August 2025. He previously served on the board of Nuance Corporation, a publicly traded communications company, until it was acquired by Microsoft Corporation in March 2022.

Mr. Brennan holds a B.S. in Finance and Investments and an M.B.A. from Babson College and is also a certified public accountant. His appointment adds deep financial and operational expertise to Vertex's board as the company continues to execute on its strategic priorities in the biotechnology sector.

GuruFocus context: GuruFocus’ GF Value™ estimates fair value near $532.86 (3.4% undervalued); its GF Score™ is 87/100; 12 gurus currently hold the stock, with 3 adding and 8 trimming positions in recent quarters — guru 13F data Simply Wall St and Morningstar don’t have. See the full Vertex Pharmaceuticals Inc VRTX research.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Averytin News Financial update.